18:08 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest the PKCE activator bryostatin-1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, administration of bryostatin-1 at the onset of muscle weakness decreased...
16:54 , Oct 17, 2017 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Synthetic chemistry A simplified multi-step method could enable scalable synthesis of the PKC modulator bryostatin-1 and its analogs to treat neurological diseases, HIV/AIDS and cancer. The method involved the total synthesis of bryostatin-1 or...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Bryostatin-1 regulatory update

Neurotrope said FDA granted Orphan Drug designation to bryostatin-1 to treat Fragile X syndrome. The protein kinase C (PKC) epsilon (PKCE) activator has completed a Phase IIa trial to treat Alzheimer’s disease (AD) (see BioCentury,...
07:00 , May 6, 2013 |  BioCentury  |  Emerging Company Profile

Neurotrope: Saving synapses

Neurotrope BioScience Inc. is developing Alzheimer's disease therapeutics targeting protein kinase C , an enzyme that could play a central role in pathology upstream of amyloid plaques and neurofibrillary tangles. The potential mechanism could explain...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Protein kinase Ce (PKCE) Studies in cell culture and in mice suggest that PKCE agonists could help treat AD. In a...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Company News

Inverness, Blanchette Rockefeller Neurosciences Institute deal

Inverness received an option to license worldwide rights to the institute's technology covering its undisclosed Alzheimer's disease biomarker to diagnose and predict disease progression and monitor treatment response. Inverness will provide the institute with research...
00:53 , Aug 19, 2006 |  BC Extra  |  Clinical News

Researchers publish skin test for AD

Researchers from Blanchette Rockefeller Neurosciences Institute published in the Proceedings of the National Academy of Sciences that an assay comparing the phosphorylation of MAP kinases ERK-1 and ERK-2 in skin fibroblasts can diagnose early Alzheimer's...
07:00 , Jul 26, 2004 |  BC Week In Review  |  Company News

Blanchette Rockefeller Neurosciences Institute other research news

In a double transgenic mouse model of AD, bryostatin 1 improved survival and behavioral outcomes compared to controls. Data were published in the Proceedings of the National Academy of Sciences. Blanchette Rockefeller Neurosciences Institute ,...